The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission
- PMID: 21285174
- PMCID: PMC3677822
- DOI: 10.3899/jrheum.100808
The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission
Abstract
Objective: Few studies have investigated whether the utility of social support for patients with a relapsing, remitting illness varies by activity level of the disease. Our goal was to determine whether disease status (relapse vs remission) moderates the effect of medication-related support from physicians and partners on the health-related quality of life (HRQOL) of patients with vasculitis.
Methods: Patients with vasculitis (n = 228) completed baseline measures of disease status and medication-related support and a 3-month followup measure of HRQOL (RAND 36-item health survey 1.0). We calculated 8 HRQOL dimensions: physical functioning, physical role limitations, bodily pain, general health, vitality, social functioning, emotional role limitations, and mental health. Bonferroni-corrected t tests compared the HRQOL of patients in relapse to patients in remission, and multivariate analysis of covariance determined whether disease status moderated the effect of medication-related support from physicians and partners on patient HRQOL. Wilks' lambda assessed whether the support-by-disease status interaction terms were significant.
Results: Relapsing patients reported significantly worse quality of life compared with nonrelapsing patients for every HRQOL dimension except physical role limitations. Disease status did not moderate the effect of physician (lambda = 0.48; p = 0.86) or partner (lambda = 1.51; p = 0.16) medication-related support on HRQOL, although greater physician and partner support predicted better HRQOL for all dimensions except bodily pain and vitality.
Conclusion: Vasculitis patients experience compromised HRQOL but the magnitude of the compromise is greater for patients experiencing a relapse. Medication-related support from physicians and partners is beneficial for patients' HRQOL regardless of disease status.
Figures
References
-
- Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int. 2007;72:676–82. - PubMed
-
- Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143:621–31. - PubMed
-
- Mukhtyar C, Luqmani R. Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin Exp Rheumatol. 2007;25(Suppl 47):120–9. - PubMed
-
- Herlyn K, Reinhold-Keller E, Zeidler A, Raspe H, Gutfleisch J, Peter HH, et al. Health-related quality of life in primary systemic vasculitides [abstract] Arthritis Rheum. 1998;41:S538. Suppl.
-
- Hoffman GS, Drucker Y, Cotch MF, Locker GA, Easley K, Kwoh K. Wegener’s granulomatosis: Patient-reported effects of disease on health, function, and income. Arthritis Rheum. 1998;41:2257–62. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical